1456 related articles for article (PubMed ID: 8851162)
21. Potency differences for D-Phe-Cys-Tyr-D-Trp-Arg-Thr-Pen-Thr-NH2 as an antagonist of peptide and alkaloid micro-agonists in an antinociception assay.
Sterious SN; Walker EA
J Pharmacol Exp Ther; 2003 Jan; 304(1):301-9. PubMed ID: 12490605
[TBL] [Abstract][Full Text] [Related]
22. Spinal interaction between the highly selective μ agonist DAMGO and several δ opioid receptor ligands in naive and morphine-tolerant mice.
Szentirmay AK; Király KP; Lenkey N; Lackó E; Al-Khrasani M; Friedmann T; Timár J; Gyarmati S; Tóth G; Fürst S; Riba P
Brain Res Bull; 2013 Jan; 90():66-71. PubMed ID: 22995282
[TBL] [Abstract][Full Text] [Related]
23. The utility of excitatory amino acid (EAA) antagonists as analgesic agents. II. Assessment of the antinociceptive activity of combinations of competitive and non-competitive NMDA antagonists with agents acting at allosteric-glycine and polyamine receptor sites.
Coderre TJ; Van Empel I
Pain; 1994 Dec; 59(3):353-359. PubMed ID: 7708409
[TBL] [Abstract][Full Text] [Related]
24. N-methyl-D-aspartate receptor antagonists potentiate the antinociceptive effects of morphine in squirrel monkeys.
Allen RM; Dykstra LA
J Pharmacol Exp Ther; 2001 Jul; 298(1):288-97. PubMed ID: 11408554
[TBL] [Abstract][Full Text] [Related]
25. Systemic morphine-induced Fos protein in the rat striatum and nucleus accumbens is regulated by mu opioid receptors in the substantia nigra and ventral tegmental area.
Bontempi B; Sharp FR
J Neurosci; 1997 Nov; 17(21):8596-612. PubMed ID: 9334431
[TBL] [Abstract][Full Text] [Related]
26. Mechanisms of μ-opioid receptor inhibition of NMDA receptor-induced substance P release in the rat spinal cord.
Chen W; Ennes HS; McRoberts JA; Marvizón JC
Neuropharmacology; 2018 Jan; 128():255-268. PubMed ID: 29042318
[TBL] [Abstract][Full Text] [Related]
27. Effect of the NMDA-antagonist, MK 801, on benzodiazepine-opioid interactions at the spinal and supraspinal level in rats.
Luger TJ; Lorenz IH; Grabner-Weiss C; Hayashi T
Br J Pharmacol; 1995 Mar; 114(5):1097-103. PubMed ID: 7780645
[TBL] [Abstract][Full Text] [Related]
28. Nonopioidergic mechanism mediating morphine-induced antianalgesia in the mouse spinal cord.
Wu HE; Thompson J; Sun HS; Leitermann RJ; Fujimoto JM; Tseng LF
J Pharmacol Exp Ther; 2004 Jul; 310(1):240-6. PubMed ID: 14999057
[TBL] [Abstract][Full Text] [Related]
29. Loss of TRPV1-expressing sensory neurons reduces spinal mu opioid receptors but paradoxically potentiates opioid analgesia.
Chen SR; Pan HL
J Neurophysiol; 2006 May; 95(5):3086-96. PubMed ID: 16467418
[TBL] [Abstract][Full Text] [Related]
30. Glutamate modulation of antinociception, but not tolerance, produced by morphine microinjection into the periaqueductal gray of the rat.
Morgan MM; Bobeck EN; Ingram SL
Brain Res; 2009 Oct; 1295():59-66. PubMed ID: 19664608
[TBL] [Abstract][Full Text] [Related]
31. Intrathecally administered big dynorphin, a prodynorphin-derived peptide, produces nociceptive behavior through an N-methyl-D-aspartate receptor mechanism.
Tan-No K; Esashi A; Nakagawasai O; Niijima F; Tadano T; Sakurada C; Sakurada T; Bakalkin G; Terenius L; Kisara K
Brain Res; 2002 Oct; 952(1):7-14. PubMed ID: 12363399
[TBL] [Abstract][Full Text] [Related]
32. Region-specific changes in NMDA receptor mRNA induced by chronic morphine treatment are prevented by the co-administration of the competitive NMDA receptor antagonist LY274614.
Zhu H; Brodsky M; Gorman AL; Inturrisi CE
Brain Res Mol Brain Res; 2003 Jun; 114(2):154-62. PubMed ID: 12829326
[TBL] [Abstract][Full Text] [Related]
33. Antinociceptive potentiation and attenuation of tolerance by intrathecal co-infusion of magnesium sulfate and morphine in rats.
McCarthy RJ; Kroin JS; Tuman KJ; Penn RD; Ivankovich AD
Anesth Analg; 1998 Apr; 86(4):830-6. PubMed ID: 9539610
[TBL] [Abstract][Full Text] [Related]
34. Effect of morphine tolerance and abstinence on the binding of [3H]naltrexone to discrete brain regions and spinal cord of the rat.
Reddy PL; Veeranna ; Matwyshyn GA; Thorat SN; Bhargava HN
Gen Pharmacol; 1994 Mar; 25(2):355-61. PubMed ID: 8026736
[TBL] [Abstract][Full Text] [Related]
35. DAMGO-induced μ opioid receptor internalization and recycling restore morphine sensitivity in tolerant rat.
Ma X; Chen R; Huang M; Wang W; Luo L; Kim DK; Jiang W; Xu T
Eur J Pharmacol; 2020 Jul; 878():173118. PubMed ID: 32320702
[TBL] [Abstract][Full Text] [Related]
36. Nitrocinnamoyl and chlorocinnamoyl derivatives of dihydrocodeinone: in vivo and in vitro characterization of mu-selective agonist and antagonist activity.
McLaughlin JP; Hill KP; Jiang Q; Sebastian A; Archer S; Bidlack JM
J Pharmacol Exp Ther; 1999 Apr; 289(1):304-11. PubMed ID: 10087018
[TBL] [Abstract][Full Text] [Related]
37. Effects of N-methyl-D-aspartate receptor antagonists on acute morphine-induced and l-methadone-induced antinociception in mice.
Fischer BD; Carrigan KA; Dykstra LA
J Pain; 2005 Jul; 6(7):425-33. PubMed ID: 15993820
[TBL] [Abstract][Full Text] [Related]
38. Effects of competitive and noncompetitive antagonists of the N-methyl-D-aspartate receptor on the analgesic action of delta 1- and delta 2-opioid receptor agonists in mice.
Bharagava HN; Zhao GM
Br J Pharmacol; 1996 Dec; 119(8):1586-90. PubMed ID: 8982505
[TBL] [Abstract][Full Text] [Related]
39. Attenuation of mu-opioid tolerance and cross-tolerance by the competitive N-methyl-D-aspartate receptor antagonist LY235959 is related to tolerance and cross-tolerance magnitude.
Allen RM; Dykstra LA
J Pharmacol Exp Ther; 2000 Dec; 295(3):1012-21. PubMed ID: 11082436
[TBL] [Abstract][Full Text] [Related]
40. N-cyclobutylmethyl analog of normorphinone, N-CBM-TAMO: a short-term opioid agonist and long-term Mu-selective irreversible opioid antagonist.
Xu JY; Seyed-Mozaffari A; Archer S; Bidlack JM
J Pharmacol Exp Ther; 1996 Nov; 279(2):539-47. PubMed ID: 8930155
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
